Continuous in vivo infusion of interferon-gamma (IFN-γ) enhances engraftment of syngeneic wild-type cells in *Fanca*−/− and *Fancg*−/− mice

Yue Si, Samantha Ciccone, Feng-Chun Yang, Jin Yuan, Daisy Zeng, Shi Chen, Henri J. van de Vrugt, John Critser, Fre Arwert, Laura S. Haneline, and D. Wade Clapp

Fanconi anemia (FA) is a heterogeneous genetic disorder characterized by bone marrow (BM) failure and cancer susceptibility. Identification of the cDNAs of FA complementation types allows the potential of using gene transfer technology to introduce functional cDNAs as transgenes into autologous stem cells and provide a cure for the BM failure in FA patients. However, strategies to enhance the mobilization, transduction, and engraftment of exogenous stem cells are required to optimize efficacy prior to widespread clinical use. Hypersensitivity of *Fancc*−/− cells to interferon-gamma (IFN-γ), a nongenotoxic immune-regulatory cytokine, enhances engraftment of syngeneic wild-type (WT) cells in *Fancc*−/− mice. However, whether this phenotype is of broad relevance in other FA complementation groups is unresolved. Here we show that primitive and mature myeloid progenitors in *Fanca*−/− and *Fancg*−/− mice are hypersensitive to IFN-γ and that in vivo infusion of IFN-γ at clinically relevant concentrations was sufficient to allow consistent long-term engraftment of isogenic WT repopulating stem cells. Given that FANCA, FANCC, and FANCG complementation groups account for more than 90% of all FA patients, these data provide evidence that IFN-γ conditioning may be a useful nongenotoxic strategy for myelopreparation in FA patients. (Blood. 2006; 108:4283-4287)

© 2006 by The American Society of Hematology

Introduction

Fanconi anemia (FA) is a heterogeneous genetic disorder characterized by a progressive bone marrow aplasia, chromosomal instability, and the acquisition of malignancies. The progressive bone marrow failure in FA and the late developing myeloid malignancies account for 90% of the mortality in FA.[1] Currently, the only cure for the hematopoietic manifestations of FA is HLA-identical allogeneic bone marrow transplantation, a therapy available to only about 30% of patients.[2] Twelve FA complementation types (FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ, FANCL, and FANCM) have been identified and the cDNAs of 11 FA genes have been sequenced.[3-10] The identification of these genes raises the potential of using gene transfer technology to express the functional cDNA into autologous stem cells. The bone marrow hypoplasia commonly observed in FA patients[1] and the reduced repopulating ability of stem cells in mice containing a disruption of the murine homologue of an FA gene[11,12] led to the hypothesis that autologous, genetically-corrected stem cells would have an engraftment and proliferation advantage. However, ex vivo culture is known to reduce stem cell engraftment in both normal murine and human cells,[13-15] and in an initial phase 1 clinical trial in FA patients where myelopreparation was not routinely performed[16] the detection of transduced cells was low in all patients. Furthermore, the most efficient engraftment of transduced cells in the clinical FA trial was observed in a single patient who received nonlethal ionizing radiation. Collectively, these data provide rationale for considering nonmyeloablative therapy prior to transplantation of autologous genetically-corrected stem cells.

FA cells exhibit increased chromosomal breaks in response to DNA-damaging agents in vitro.[3,17] Thus there is a theoretical potential of FA patients having an increased incidence for secondary malignancies following myelopreparation with genotoxic agents. Due to the low frequency of FA in the general population[18] and the high incidence of malignant predisposition of FA patients, it is difficult to fully ascertain the risk associated with the genotoxic myelopreparation regimen in patients. However, several studies suggest an increased risk for hematopoietic and nonhematopoietic secondary malignancies[19-22] after hematopoietic stem cell transplantation in FA patients. For these reasons, a nongenotoxic myelopreparative regimen would be ideal in selecting genetically-corrected stem cells in vivo.

Interferon-gamma (IFN-γ) is a nongenotoxic immunoregulatory lymphokine with a high therapeutic index[23] that has been used to treat a number of malignancies.[24-26] Rathbun et al provided the first evidence that murine *(Fancc*−/− *)* and human (FANCC) hematopoietic cells were hypersensitive to IFN-γ via an increase in apoptosis.[27] These results were subsequently confirmed in an independent *Fancc*−/− murine model in vitro and in vivo.[28,29] Previous work indicates that a mechanism for the hypersensitivity of FANCC-deficient cells to IFN-γ is mediated by FANCC physically interacting with heat shock protein 70 to inhibit PKR activation and apoptosis.[30] Subsequent studies showed that FANCA and FANCG also participate in that complex.[31] FANCA progenitors were found to be hypersensitive to IFN-γ via an increase in apoptosis in that same study.[31] However, one in vitro study in a

murine model of FANCA (Fanca[−/−]) was unable to detect an increase in the sensitivity of Fanca[−/−] myeloid progenitors to IFN-γ compared with wild-type (WT) controls.[32] Whether the differing results of the human FANCA and murine (Fanca[−/−]) studies reflect differences in in vitro protocols or, alternatively, species-specific differences remains unclear. Studies to determine whether Fanca[−/−] or Fancg[−/−] progenitors are hypersensitive to IFN-γ in vivo have not been attempted. Since FANCA, FANCG, and FANCC patients collectively account for 90% of all FA patients,[1] determination of the hypersensitivity of hematopoietic progenitors from these complementation groups to IFN-γ could have broad relevance to the potential of IFN-γ in nongenotoxic myelopreparation. Here we tested the hypothesis that IFN-γ can be used as a single myelopreparative agent in Fanca[−/−] and Fancg[−/−] mice prior to transplantation of isogenic repopulating stem cells. Our results demonstrate that both primitive and mature Fanca[−/−] and Fancg[−/−] myeloid progenitors are hypersensitive to IFN-γ treatment in vitro and in vivo compared with syngeneic WT progenitors, similar to Fancc[−/−] mice. In addition, continuous subcutaneous infusion of IFN-γ facilitated the engraftment of consistently high levels of exogenous, isogeneic WT hematopoietic stem/progenitor cells. These data support the hypothesis that IFN-γ may be useful as a nongenotoxic, myelopreparative regimen in multiple FA complementation groups.

Materials and methods

Mice

The Fanca[+/−] and Fancg[+/−] lines used in these studies have been previously described.[33,34]

Fanca[+/−] mice (C57Bl/6 × SV129), Fancg[+/−] mice, and Fancc[+/−] mice were backcrossed into a C57Bl/6J strain (CD45.2[+]) and then bred to generate Fanca[−/−] or Fancg[−/−] and WT mice. Congenic C57Bl/6J (CD45.2[+]) and B6.SJL-PtrcaPep3b/BoyJ (B6.BoyJ) mice (CD45.1[+]) were purchased from Jackson Laboratories (Bar Harbor, ME) and maintained in our animal facility.[12]

Treatment and monitoring

All experimental mice were housed in the Indiana University School of Medicine Laboratory Animal Resource Center and examined regularly by one of the investigators. Murine IFN-γ was purchased from Peprotech (Rocky Hill, NJ), reconstituted as recommended by the manufacturer, and placed within micro-osmotic pumps to administer a defined volume (0.5 μL/h for 7 days; DURECT, Cupertino, CA). Micropumps containing either IFN-γ or phosphate-buffered saline (PBS) were implanted subcutaneously into the backs of WT, Fancc[−/−], Fanca[−/−], and Fancg[−/−] mice and removed following a 7-day infusion. IFN-γ was administered at a dosage of 0 or 400 μg/kg per day. These studies were reviewed and approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee.

Complete peripheral blood counts were obtained using an automated cell counter (Sysmex, Kobe, Japan) 7 days after treatment. The accuracy of abnormal blood counts was verified by direct examination of blood smears. Renal and hepatic functions of the mice were also examined. Spleen weight and bone marrow (BM) cellularity were determined. The hematopoietic tissues were collected for clonogenic assays and histologic analysis.

Isolation of bone marrow

Bone marrow cells were flushed from the tibiae and femurs using Iscoves modified Dulbecco media (IMDM; Gibco-BRL, Gaithersburg, MD) containing 5% fetal calf serum (FCS; Hyclone Laboratories, Logan, UT). Low-density mononuclear cells (LDMNCs) were prepared by centrifugation on ficoll-hypaque (density, 1.119; Sigma, St Louis, MO).[28]

Hematopoietic progenitor growth

Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 3 (IL-3), and stem cell factor (SCF) were obtained from Peprotech; recombinant murine IL-1 (mIL-1) and macrophage CSF (M-CSF) were purchased from R&D Research Laboratories (Minneapolis, MN). LDMNCs were placed into culture in triplicate 35-mm plates (Becton Dickinson, Franklin Lakes, NJ) at a final concentration of 2×10^4 LDMNCs or 5×10^5 spleen LDMNCs per plate. To culture low proliferating potential colony-forming cells (LPP-CFCs) and high proliferating potential colony-forming cells (HPP-CFCs), LDMNCs and recombinant growth factors were added to (0.66%-1.0%) agar, and the solution was thoroughly mixed before plating as previously described.[35] Growth factors used for culture of HPP-CFCs and LPP-CFCs included SCF, IL-1, M-CSF, GM-CSF, and IL-3.[35] To evaluate growth-inhibitory effects of IFN-γ on progenitor cells, LDMNCs were plated in the absence or presence of IFN-γ (0.3-1 ng/mL) in clonogenic assays as described elsewhere.[28]

Evaluation of IFN-γ as a myelopreparative conditioning agent

Fancc[−/−], Fanca[−/−], Fancg[−/−], and WT mice (CD45.2[+]) were treated with 400 μg/kg per day IFN-γ or PBS for 7 days as described in "Treatment and monitoring" and then received transplants of 1×10^7 BM nucleated B6.BoyJ cells (CD45.1[+]). The percentage of CD45.1[+] cells in the peripheral blood was analyzed at 1, 4, and 6 months after transplantation as described previously.[11,36] To evaluate multilineage reconstitution of donor CD45.1[+] cells, peripheral blood of IFN-γ–treated or untreated mice was costained with phycoerythrin (PE)–conjugated lineage marker antibodies (Gr1, Mac1, B220, and CD3; BD PharMingen, San Diego, CA) and fluorescein isothiocyanate (FITC)–conjugated CD45.1 antibody (BD Phar-Mingen) and analyzed by fluorescence cytometry 6 months following transplantation. Six months following transplantation, secondary transplantation studies were conducted using BM cells from IFN-γ–treated or untreated recipients as donor cells.

Statistical analyses

Computations were carried out using the Graph Pad Prism software package (San Diego, CA). Statistical comparisons among all groups were compared using analysis of variance and Student t test. A P value less than .05 was considered statistically significant.

Results

Fanca[−/−] and Fancg[−/−] progenitors are hypersensitive to IFN-γ treatment in vitro

To compare the sensitivity of Fanca[−/−] and Fancg[−/−] myeloid progenitors to Fancc[−/−] and WT myeloid progenitors, clonogenic assays for the growth of CFU-GMs were established in a range of IFN-γ concentrations. The mean ± the standard error of the mean of 4 independent experiments is shown in Figure 1. Consistent with previous studies,[27,28] Fancc[−/−] myeloid progenitors were hypersensitive to IFN-γ compared with WT control cells. Fanca[−/−] and Fancg[−/−] progenitors exhibited a sensitivity to IFN-γ that was comparable with Fancc[−/−] myeloid progenitors.

In vivo administration of IFN-γ results in a reduction of primitive and mature hematopoietic progenitor cell populations in Fanca[−/−] and Fancg[−/−] mice

To determine whether Fanca[−/−] and Fancg[−/−] myeloid progenitors are hypersensitive to IFN-γ in vivo comparable with concentrations used clinically,[23,24] osmotic micropumps containing IFN-γ were implanted subcutaneously into the backs of age-matched Fanca[−/−], Fancg[−/−], Fancc[−/−], and WT mice to deliver 400 μg/kg per day IFN-γ or PBS alone for 7 days. The peripheral white blood

Figure 1. Evaluation of the sensitivity of *Fanca*⁻/⁻ and *Fancg*⁻/⁻ myeloid progenitors to IFN-γ. Methylcellulose cultures that promote the growth of myeloid progenitors from FA-deficient bone marrow were established containing a range of concentrations of IFN-γ in triplicate wells. The respective genotypes are indicated. Data represent the mean ± standard error of the mean (SEM) of 4 independent experiments. *$P < .01$ comparing the IFN-γ–dependent reduction in myeloid progenitors of *Fancc*⁻/⁻, *Fanca*⁻/⁻, and *Fancg*⁻/⁻ myeloid progenitors to wild-type controls using analysis of variance.

cell (WBC) counts of all genotypes were similar following the administration of PBS (Figure 2A). Administration of IFN-γ had no significant reduction in the peripheral WBC count of WT mice following a 7-day infusion of 400 μg/kg per day IFN-γ. Similarly, IFN-γ treatment had no effect on the hematocrit or platelet counts in any genotype compared with mice treated with vehicle control (data not shown). However, the peripheral WBC counts of *Fanca*⁻/⁻ and *Fancg*⁻/⁻ mice had a significant reduction in peripheral WBC counts, similar to that observed in *Fancc*⁻/⁻ mice. A similar decrease in bone marrow cellularity was observed in all complementation groups of FA-deficient mice (Figure 2B).

In order to determine the effect of IFN-γ treatment on primitive and mature hematopoietic progenitors in vivo, high proliferative

potential colony-forming cells (HPP-CFC) and low proliferative potential colony-forming cells (LPP-CFC) were cultured from bone marrow of the respective genotypes. Even in the absence of IFN-γ treatment, *Fanca*⁻/⁻ and *Fancg*⁻/⁻ mice, similar to *Fancc*⁻/⁻ mice, had a reduction in the number of HPP-CFCs per femur compared with WT mice (Figure 3A). Of importance, following administration of IFN-γ, a dramatic reduction in the number of HPP-CFCs and LPP-CFCs was observed in all 3 FA complementation groups compared with equivalently-treated WT mice (Figure 3B). Similar reductions were observed in burst-forming unit–erythroid (BFU-E) and multipotent myeloid progenitors (CFU-GEMM) (data not shown). Collectively, these data indicate that in vivo IFN-γ treatment preferentially reduces the number of primitive and mature myeloid progenitors in all 3 genotypes of FA-deficient mice.

Enhanced engraftment of WT hematopoietic cells in *Fanca*⁻/⁻ and *Fancg*⁻/⁻ mice pretreated with IFN-γ

To determine whether the myelopreparative protocol with IFN-γ is sufficient to allow engraftment and proliferation of isogenic WT repopulating cells, 10^7 WT CD45.1⁺ BM nucleated cells were transplanted into *Fanca*⁻/⁻, *Fancg*⁻/⁻, *Fancc*⁻/⁻, and WT animals pretreated with IFN-γ or PBS. Figure 4A shows the chimerism of individual recipients in 1 of 2 independent experiments with similar results. The percentage of CD45.1⁺ donor cells in peripheral blood was examined using fluorescence cytometry 4 months following transplantation. Isogenic cells failed to engraft and contribute to hematopoiesis in any of the 3 respective FA or WT experimental groups following treatment with vehicle only (Figure 4A). IFN-γ was not sufficient to allow engraftment of exogenous, isogenic BM cells into WT recipients (Figure 4A). However, both *Fanca*⁻/⁻ and *Fancg*⁻/⁻ recipients treated with IFN-γ prior to transplantation had a significant donor chimerism in peripheral blood 4 months following transplantation comparable with the donor chimerism of *Fancc*⁻/⁻ mice. Representative FACS analyses showing multilineage reconstitution in *Fanca*⁻/⁻ and *Fancg*⁻/⁻ mice (Figure 4B-C) are shown.

Figure 2. Effects of in vivo IFN-γ treatment on peripheral white blood cell (WBC) counts and bone marrow cellularity. (A) Peripheral nucleated cell counts were obtained from experimental mice following completion of IFN-γ treatment (closed symbols) or the phosphate-buffered saline vehicle, PBS (open symbols). Each symbol represents total nucleated white blood cells from individual mice. Bars represent the mean WBC count of all experimental mice in the respective treatment group. *$P < .01$ comparing white blood cell counts of IFN-γ–treated mice to vehicle-treated control mice with the same genotype. (B) BM cellularity following IFN-γ treatment. Symbols represent bone marrow cellularity of individual mice. Bars represent the mean BM cellularity of all mice in the experimental group. *$P < .01$ comparing bone marrow cellularity of IFN-γ–treated mice versus vehicle-treated controls of the same genotype.


Figure 3. Evaluation of IFN-γ on primitive and mature myeloid progenitor numbers isolated from the BM of *Fanca*⁻/⁻, *Fancg*⁻/⁻, and *Fancc*⁻/⁻ mice. (A) Evaluation of myeloid progenitors from WT, *Fancc*⁻/⁻, *Fanca*⁻/⁻, and *Fancg*⁻/⁻ bone marrow. Hematopoietic cells derived from the bone marrow LDMNCs from mice of each respective genotype were cultured in triplicate to evaluate growth of high proliferating potential colony-forming cells (HPP-CFCs) and low proliferating potential colony-forming cells (LPP-CFCs). Data represent the mean ± standard error of the mean (SEM) of 3 independent experiments. (B) Bone marrow cells from WT, *Fancc*⁻/⁻, *Fanca*⁻/⁻, and *Fancg*⁻/⁻ mice previously treated with a 7-day course of 400 μg/kg per day IFN-γ or vehicle control were cultured at 2×10^4 BM LDMNCs/mL to determine the reduction in the respective populations of progenitors. Data represent the mean ± standard error of the mean (SEM) of 3 independent experiments.

Figure 4. IFN-γ treatment of *Fanca−/−* and *Fancg−/−* recipients is sufficient to allow engraftment of syngeneic WT bone marrow cells. (A) CD45.1+ WT BM nucleated cells (10⁷) were injected into the tail vein of *Fanca−/−* and *Fancg−/−* C57Bl/6 recipients that express the CD45.2 antigen. Recipients were pretreated with IFN-γ or vehicle control. The percentage of CD45.1+ cells in the peripheral blood was determined by fluorescence cytometry 6 months following transplantation. WT and *Fancc−/−* mice treated with PBS or IFN-γ were used as controls. Data points represent CD45.1+ chimerism of individual mice. Bars represent the mean CD45.1+ chimerism. *P < .001 comparing chimerism of *Fanca−/−* or *Fancg−/−* recipients treated with IFN-γ versus vehicle-treated *Fanca−/−* recipients and *Fancg−/−* recipients. Multilineage analysis of donor CD45.1 cells in representative (B) *Fanca−/−* and (C) *Fancg−/−* mice. The percentage of WT CD45.1+ lymphoid (CD3 and B220) and myeloid (Gr1 and Mac1) cells is shown in the top right corner of each fluorescence-activated cell sorter (FACS) profile.

To confirm that IFN-γ myelopreparation was sufficient to allow engraftment of donor long-term repopulating stem cells, 2 million BM LDMNCs from selected primary recipients of a second cohort were transplanted into irradiated, secondary recipients and their chimerism was evaluated 6 months following transplantation (Figure 5A-B). The chimerism of recipients that received BM cells from *Fanca−/−* or *Fancg−/−* mice previously given the vehicle control only as a myelopreparative agent was low as expected. However, the chimerism of secondary recipients who received bone marrow cells from IFN-γ–treated *Fanca−/−* (Figure 5A) and *Fancg−/−* (Figure 5B) recipients consistently retained high chimerism. The bone marrow and splenic cellularity of these recipients at postmortem exam was normal comparable with previous studies in *Fancc−/−* mice (data not shown). Collectively, these data indicate that in vivo administration of IFN-γ in *Fanca−/−* and *Fancg−/−* mice is sufficient as a myelopreparative agent to enhance the engraftment of repopulating syngeneic WT cells in *Fanca−/−* and *Fancg−/−* mice.

Discussion

Although palliative therapy has improved the survival of patients with Fanconi anemia over the past 10 years,[1] bone marrow failure remains the leading cause of death.[37] Allogenic bone marrow transplantation or cord blood transplantation is available to a subset of these patients.[2] However, for individuals who lack an HLA-compatible donor, non–HLA-matched transplantation is rarely used because of the particularly high morbidity of this therapy in

FA patients.[38] Thus transplantation of genetically-corrected autologous stem cells remains an important potential therapy for this uniformly fatal disease.

In addition to the usual challenges in gene transfer protocols, FA disease itself creates an additional set of potential obstacles. Patients that are considered for gene transfer often have bone marrow hypoplasia.[37] In addition, emerging data in FA patients[39] and in *Fancc−/−* mice[40] suggests that granulocyte colony-stimulating factor, the current cornerstone of stem cell mobilization, inefficiently mobilizes FA-deficient stem/progenitor cells. Further, the propensity of *Fancc−/−* cells to apoptosis ex vivo[12] and the known challenges in homing of ex vivo–cultured cells[41] are additional challenges in having an adequate graft of genetically-transduced cells. These observations, together with previous clinical data showing that patients with FA have an increased risk for secondary malignancies following genotoxins,[19,20,42-44] have provided the impetus for considering IFN-γ as a myelopreparative conditioning agent in FA preclinical models as a proof of concept.

Given previous in vitro and in vivo studies demonstrating that *Fancc−/−* cells are hypersensitive to IFN-γ, we evaluated whether a similar phenotype is present in other FA complementation groups. In 2 independent studies (6-7 mice per study group), we found that continuous subcutaneous infusion of IFN-γ enhances the engraftment of WT cells in *Fanca−/−* and *Fancg−/−* mice. The high level of engraftment was maintained in secondary recipients, indicating the engraftment of long-term repopulating stem cells. The treatment of IFN-γ was well tolerated in all the genotyped mice tested in the study. No severe hematologic sequelae were observed in the IFN-γ–treated mice in either primary or secondary recipients. The establishment of the IFN-γ BM conditioning in *Fanca−/−*, *Fancg−/−*, and *Fancc−/−* models could have implications in using this approved drug in the clinic as a means to enhance the engraftment of exogenous genetically-corrected stem/progenitor cells.


Figure 5. IFN-γ treatment of *Fanca−/−* recipients is sufficient to allow long-term engraftment of syngeneic WT bone marrow cells. Six months following transplantation with CD45.1+ WT donor BM nucleated cells, selected recipients from a second cohort of (A) *Fanca−/−* or (B) *Fancg−/−* mice received transplants from secondary recipients to verify that the engrafting CD45.1 donor cells were long-term repopulating stem cells. The CD45.1+ chimerism of each primary recipient (left panels) and the chimerism of 3 secondary recipients (right panels) from each respective primary recipient are indicated. Bars represent the mean CD45.1+ chimerism. *P < .001 comparing chimerism of *Fanca−/−* and *Fancg−/−* recipients treated with IFN-γ versus vehicle-treated *Fanca−/−* and *Fancg−/−* recipients.

Acknowledgments

Authorship

Conflict-of-interest disclosure: the authors declare no competing financial interests.

Correspondence: D. Wade Clapp, Cancer Research Institute, 1044 W Walnut St, Rm 402, Indianapolis, IN 46202-5254; e-mail: dclapp@iupui.edu.

References

1. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101:1249-1256.

2. Gluckman E, Auerbach AD, Horowitz MM, et al. Bone marrow transplantation for Fanconi anemia. Blood. 1995;86:2856-2862.

3. Thompson LH. Unraveling the Fanconi anemia-DNA repair connection. Nat Genet. 2005;37:921-922.

4. Meetei AR, Sechi S, Wallisch M, et al. A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Mol Cell Biol. 2003;23:3417-3426.

5. Levitus M, Rooimans MA, Steltenpool J, et al. Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. Blood. 2004;103:2498-2503.

6. Meetei AR, Medhurst AL, Ling C, et al. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat Genet. 2005;37:958-963.

7. Levitus M, Waisfisz Q, Godthelp BC, et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet. 2005;37:934-935.

8. Levran O, Attwooll C, Henry RT, et al. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet. 2005;37:931-933.

9. Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2001;2:446-459.

10. Taniguchi T, Dandrea AD. Molecular pathogenesis of Fanconi anemia. Int J Hematol. 2002;75:123-128.

11. Haneline LS, Gobbett TA, Ramani R, et al. Loss of FancC function results in decreased hematopoietic stem cell repopulating ability. Blood. 1999;94:1-8.

12. Li X, Le Beau MM, Ciccone S, et al. Ex vivo culture of Fancc-/- stem/ progenitor cells predisposes cells to undergo apoptosis and surviving stem/progenitor cells display cytogenetic abnormalities and an increased risk of malignancy. Blood. 2005;105:3465-3471.

13. Quesenberry PJ, Colvin G, Abedi M. Perspective: fundamental and clinical concepts on stem cell homing and engraftment: a journey to niches and beyond. Exp Hematol. 2005;33:9-19.

14. Jetmore A, Plett PA, Tong X, et al. Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34(+) cells transplanted into conditioned NOD/SCID recipients. Blood. 2002;99:1585-1593.

15. Orschell-Traycoff CM, Hiatt K, Dagher RN, Rice S, Yoder MC, Srour EF. Homing and engraftment potential of Sca-1(+)lin(-) cells fractionated on the basis of adhesion molecule expression and position in cell cycle. Blood. 2000;96:1380-1387.

16. Liu JM, Kim S, Read EJ, et al. Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). Hum Gene Ther. 1999;10:2337-2346.

17. D'Andrea AD. The Fanconi road to cancer. Genes Dev. 2003;17:1933-1936.

18. Schroeder TM, Tilgen D, Kruger J, Vogel F. Formal genetics of Fanconi's anemia. Hum Genet. 1976;32:257-288.

19. Socie G, Scieux C, Gluckman E, et al. Squamous cell carcinomas after allogeneic bone marrow transplantation for aplastic anemia: further evidence of a multistep process. Transplantation. 1998;66:667-670.

20. Socie G, Devergie A, Girinski T, et al. Transplantation for Fanconi's anaemia: long-term follow-up of fifty patients transplanted from a sibling donor after low- dose cyclophosphamide and thoraco-abdominal irradiation for conditioning. Br J Haematol. 1998;103:249-255.

21. Guardiola P, Socie G, Pasquini R, et al. Allogeneic stem cell transplantation for Fanconi anaemia: Severe Aplastic Anaemia Working Party of the EBMT and EUFAR: European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998;21(suppl 2):S24-S27.

22. Rosenberg PS, Socie G, Alter BP, Gluckman E. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood. 2005;105:67-73.

23. Ernstoff MS, Trautman T, Davis CA, et al. A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol. 1987;5:1804-1810.

24. Liles WC. Immunomodulatory approaches to augment phagocyte-mediated host defense for treatment of infectious diseases. Semin Respir Infect. 2001;16:11-17.

25. Borden EC, Lindner D, Dreicer R, Hussein M, Peereboom D. Second-generation interferons for cancer: clinical targets. Semin Cancer Biol. 2000;10:125-144.

26. Tower PA, Christianson TA, Peters ST, et al. Expression of the Fanconi anemia group C gene in hematopoietic cells is not influenced by oxidative stress, cross- linking agents, radiation, heat, or mitotic inhibitory factors. Exp Hematol. 1998;26:19-26.

27. Rathbun RK, Faulkner GR, Ostroski MH, et al. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. Blood. 1997;90:974-985.

28. Haneline LS, Broxmeyer HE, Cooper S, et al. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice. Blood. 1998;91:4092-4098.

29. Li X, Yang Y, Yuan J, et al. Continuous in vivo infusion of interferon-gamma (IFN-{gamma}) preferentially reduces myeloid progenitor numbers and enhances engraftment of syngeneic wildtype cells in Fancc-/- mice. Blood. 2004;104:1204-1209.

30. Pang Q, Keeble W, Christianson TA, Faulkner GR, Bagby GC. FANCC interacts with Hsp70 to protect hematopoietic cells from IFN-gamma/TNF-alpha-mediated cytotoxicity. EMBO J. 2001;20:4478-4489.

31. Zhang X, Li J, Sejas DP, Rathbun KR, Bagby GC, Pang Q. The Fanconi anemia proteins functionally interact with the protein kinase regulated by RNA (PKR). J Biol Chem. 2004;279:43910-43919.

32. Noll M, Battaile KP, Bateman R, et al. Fanconi anemia group A and C double-mutant mice: functional evidence for a multi-protein Fanconi anemia complex. Exp Hematol. 2002;30:679-688.

33. Yang Y, Kuang Y, De Oca RM, et al. Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9. Blood. 2001;98:3435-3440.

34. Cheng NC, van de Vrugt HJ, van der Valk MA, et al. Mice with a targeted disruption of the Fanconi anemia homolog Fanca. Hum Mol Genet. 2000;9:1805-1811.

35. Zhang Y, Vik TA, Ryder JW, et al. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med. 1998;187:1893-1902.

36. Haneline LS, Li X, Ciccone SL, et al. Retroviral-mediated expression of recombinant Fancc enhances the repopulating ability of Fancc-/- hematopoietic stem cells and decreases the risk of clonal evolution. Blood. 2003;101:1299-1307.

37. Bagby GC, Lipton JM, Sloand EM, Schiffer CA. Marrow failure. Hematology (Am Soc Hematol Educ Program). 2004:318-336.

38. Kook H. Fanconi anemia: current management. Hematology. 2005;10(suppl 1):108-110.

39. Croop JM, Cooper R, Fernandez C, et al. Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia. Blood. 2001;98:2917-2921.

40. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201:1307-1318.

41. Szilvassy SJ, Bass MJ, Van Zant G, Grimes B. Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by ex vivo expansion. Blood. 1999;93:1557-1566.

42. Deeg HJ, Socie G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386-392.

43. Alter BP. Fanconi's anemia and malignancies. Am J Hematol. 1996;53:99-110.

44. Alter BP, Greene MH, Velazquez I, Rosenberg PS. Cancer in Fanconi anemia [letter]. Blood. 2003;101:2072.